Leaders among biopharmaceuticals

Top 10 Biotechnological Blockbuster DrugsAccording to Pharma2020, this year the well-known FiercePharma website published a list of 10 biotechnological blockbuster drugs (according to sales data in 2008). Recall that an innovative (branded) drug with annual sales of at least $ 1 billion is considered a blockbuster.

1. Enbrel (Etanercept)
Companies: Amgen, Wyeth, Takeda
Sales: $7.66 billion
Appointments: Rheumatoid arthritis, adolescent arthritis, ankylosing spondylitis, plaque psoriasis.

2. Remicade (Infliximab)
Companies: J&J, Schering Plough, Mitsubishi Tanabe
Sales: $6.2 billion
Appointments: Plaque psoriasis, rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults, Crohn's disease in children, ulcerative colitis, ankylosing spondylitis 3. Rituxan

3. Rituxan (Rituximab)
Company: Roche
Sales: $5.5 billion
Appointments: Non-Hodgkin's lymphoma and rheumatoid arthritis

4. Avastin (Bevacizumab)
Company: Roche Sales: $3.8 billion
Appointments: Metastatic rectal cancer, non-small cell lung cancer, metastatic breast cancer, glioblastoma, metastatic kidney cancer.

5. Herceptin (Trastuzumab)
Company: Roche
Sales: $4.7 billion
Appointments: Breast cancer.

6. Humira (Adalimumab)
Company: Abbott
Sales: $4.5 billion
Appointments: Rheumatoid arthritis, multi-articular adolescent arthritis, psoriatic arthritis, chronic plaque psoriasis, ankylosing spondylitis, Crohn's disease.

7. Lovenox (Enoxaparin)
Company: Sanofi Aventis
Sales: $4 billion
Appointments: from blood clots with deep vein thrombosis.

8. Lantus (Insulin)
Company: Sanofi Aventis
Sales: $3.6 billion
Appointments: Diabetes.

9. Aranesp (Darbepoetin)
Company: Amgen
Sales: $3.1 billion
Appointments: Anemia.

10. Gardasil
Company: Merck
Sales: $2.8 billion
Appointments: Human Pappilomavirus and prevention of cervical cancer.

Portal "Eternal youth" http://vechnayamolodost.ru10.12.2009